MIM
FATE icon

MetLife Investment Management’s Fate Therapeutics FATE Stock Holding History

MetLife Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-67,990
Closed -$76.1K – 2874
2025
Q2 		$76.1K Buy
+67,990
New +$79K ﹤0.01% 2653
2025
Q1 		– Sell
-16,641
Closed -$27.5K – 2794
2024
Q4 		$27.5K Sell
16,641
-26,011
-61% -$65.5K ﹤0.01% 2781
2024
Q3 		$149K Sell
42,652
-17,337
-29% -$67.5K ﹤0.01% 2437
2024
Q2 		$197K Buy
59,989
+21,660
+57% +$94.8K ﹤0.01% 2253
2024
Q1 		$281K Sell
38,329
-5,675
-13% -$35.1K ﹤0.01% 1994
2023
Q4 		$165K Hold
44,004
– – ﹤0.01% 2345
2023
Q3 		$93.3K Hold
44,004
– – ﹤0.01% 2615
2023
Q2 		$209K Hold
44,004
– – ﹤0.01% 2248
2023
Q1 		$251K Hold
44,004
– – ﹤0.01% 2084
2022
Q4 		$444K Hold
44,004
– – ﹤0.01% 1713
2022
Q3 		$986K Hold
44,004
– – 0.01% 1198
2022
Q2 		$1.09M Hold
44,004
– – 0.01% 1168
2022
Q1 		$1.71M Buy
44,004
+15,638
+55% +$606K 0.01% 1062
2021
Q4 		$1.66M Hold
28,366
– – 0.01% 932
2021
Q3 		$1.68M Hold
28,366
– – 0.02% 927
2021
Q2 		$2.46M Hold
28,366
– – 0.02% 779
2021
Q1 		$2.34M Sell
28,366
-210
-0.7% -$20.1K 0.02% 809
2020
Q4 		$2.6M Sell
28,576
-1,683
-6% -$105K 0.02% 704
2020
Q3 		$1.21M Buy
30,259
+3,344
+12% +$117K 0.01% 941
2020
Q2 		$923K Hold
26,915
– – 0.01% 1070
2020
Q1 		$598K Hold
26,915
– – 0.01% 1121
2019
Q4 		$527K Buy
26,915
+3,655
+16% +$58K 0.01% 1437
2019
Q3 		$361K Sell
23,260
-4,623
-17% -$88.6K ﹤0.01% 1590
2019
Q2 		$566K Sell
27,883
-55,766
-67% -$1M 0.01% 1404
2019
Q1 		$1.47M Buy
83,649
+55,766
+200% +$880K ﹤0.01% 1439
2018
Q4 		$358K Buy
27,883
+4,805
+21% +$67K ﹤0.01% 1567
2018
Q3 		$376K Hold
23,078
– – ﹤0.01% 1716
2018
Q2 		$262K Hold
23,078
– – ﹤0.01% 1783
2018
Q1 		$225K Buy
+23,078
New +$221K ﹤0.01% 1823

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MetLife Investment Management's FATE Position: Q3 2025 in Review

MetLife Investment Management sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 67,990 shares — an estimated $76.1K sold.

MetLife Investment Management first reported a position in FATE in Q1 2018 and held it in 29 quarters. The position peaked at $2.6M in Q4 2020. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • MetLife Investment Management reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • MetLife Investment Management sold 67,990 Fate Therapeutics shares in Q3 2025, an estimated $76.1K.
  • MetLife Investment Management first reported a position in Fate Therapeutics in Q1 2018 and held it in 29 quarters.
  • MetLife Investment Management's Fate Therapeutics position peaked at $2.6M in Q4 2020.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.